Human Reproductive Technologies

Published by: Global Industry Analysts

Published: Oct. 1, 2006 - 496 Pages

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

A. Fertility Enhancement Drugs

B. Fertility Technologies and Procedures

C. Contraceptives and Abortion

Oral Contraceptives

Condoms

Implants/Injections

D. Reproduction-Assisted Diagnostics

II. EXECUTIVE SUMMARY

1. Industry Overview

Segmental Perspective

Regional Perspective

Trends & Issues

Lack of Awareness May Plague Reproductive Health

Lifestyle Trends Lead to Strong Increase in Fertility Treatments Market

New Product Development Trends

Variations in Distribution Patterns

Demographic Variables Will Boost Infertility Market

Table 1: Pregnancy Rates Among Women in their Childbearing Age: A Peek Into Empirical Evidence that Conception Decreases With Age (includes corresponding Graph/Chart)

Table 2: World Fertility Rates: Breakdown by Country by Total Fertility Rate (TFR) for the Year 2005

Table 3: Female Population in the Ripe Childbearing Age (15-35) in Select Countries in Asia for the Years 2005 & 2010 (In Millions) (includes corresponding Graph/Chart)

Market for Modern Contraceptives Picking Up in Developing Regions

Table 4: Comparative Study of Modern Contraception Methods in Developing Regions (including India & China) and Developing Regions (excluding India & China) - Percentage of Married Women Using Oral Contraceptives, Female Sterilization, and Intrauterine Devices (IUDs): Recent Past Data for 2000

Table 5: Worldwide Contraceptive Market: Prevalence Amongst Women (2000-2025) - Percentage Share by Asia, Latin America and Africa (includes corresponding Graph/Chart)

Condom Sales on Rise

The Cascading Impact of High Fertility Rates in Developing Countries

Modern Women Wield Greater Control Over Their Reproductive Lives

Accuracy of Pregnancy Tests: A Key Issue

ART: Cost and Coverage Issues

Controversies on Human Cloning

2. A Preface to Human Reproductive System

Reproduction

Male Reproductive System

Female Reproductive System

The Dynamics of Reproductive Endocrinology

Human Reproductive Technologies

3. Fertility Enhancement

What is Infertility?

Infertility and Sexual Dysfunction

Female Infertility: Causes & Treatment

Ovulation Factors

Cervical Factors

Tubal Factors

Uterine/Endometrial Factors

Endometriosis

Unknown/Unexplained Factors

Male Infertility: Causes & Treatment

Azoospermia

Ejaculation Dysfunction

Seminal Tract Washout

Other Procedures

Fertility Enhancement Drugs

Fertility Enhancement Drugs: A Peek into the Major Brands

Fertility Technologies and Procedures

Assisted Reproductive Technologies

The ART Cycle

The ART Success Rates

ART Success Rates: Classification by Maternal Age and Male Factor

In Vitro Fertilization (IVF)

Gamete intrafallopian transfer (GIFT)

Zygote intrafallopian transfer (ZIFT)

Intracytoplasmic sperm injection (ICSI)

Tubal Embryo Transfer

Artificial Insemination

Artificial Insemination by Husband (AIH)

Artificial Insemination By Donor (AID)

Ooplasmic Transfer

Assisted Hatching

Sperm, Oocytes, and Embryo Donation

Surrogacy

Assisted Reproduction: A Boon or Bane?

ART Merits

ART Demerits

Multiple Births

Misappropriation of Embryos, Eggs

Ovarian Hyperstimulation Syndrome

Sex Selection

Designer Children

4. Contraceptives and Abortion

Contraception

Contraceptive Methods

Barrier Contraceptives

Condoms

Male Condom

Male Condom - Effectiveness of Protection Against STDs

Female Condom

Spermicides

Diaphragms

Cervical Cap

Sponges

Vaginal Contraceptive Film

Hormonal Contraceptives

Oral Contraceptives

Major Oral Contraceptives At a Glance

Implantable Hormones

Transdermal or Contraceptive Patch

NuvaRing Vaginal Ring

Injectable Contraceptives

Depo-Provera

Lunelle

Norplant

Mirena

Emergency Contraceptives

How Emergency Contraceptive Works?

Types of EC

Mini Pills (or Plan B®)

RU486 - the Abortion Pill

Prescription Contraceptive Devices

Intrauterine Devices (IUDs)

CopperT 380A (ParaGard)

Progesterone T (or Progestasert)

Traditional/Natural Method

Withdrawal

Douching

Abstinence

Rhythm

Permanent Methods

Sterilization

Procedures for Women

Tubal Ligation

Laparoscopy

Mini-Laparotomy

Laparotomy

Culdoscopy

Colpotomy

Hysterectomy

Selective Tubal Occlusion Procedure (STOP)

Procedures for Men

Vasectomy

Contraception - Levels of Effectiveness

Table 6: Contraceptive Use by Women Aged 15-44 (Recent Past Data for 2003) - Global Percentage Breakdown by Method - Oral Pill, Sterilization, Condom, Vasectomy, Withdrawal, Injection, Periodic Abstinence, Diaphragm, Implants, IUD and Others (includes corresponding Graph/Chart)

Contraceptives and their Use in Major Regions Worldwide

Abortion

Abortion Procedures

Medical Abortion

Mifepristone

Methotrexate

Surgical Procedures

Vacuum Aspiration

Dilation and Curettage

Dilation and Evacuation

Induction Abortion

Hysterotomy or Caesarean Section

5. Reproduction Assisted Diagnostics

Infertility Diagnostics

Female Infertility Diagnosis

Falloposcopy

Hysteroscopy

Endometrial Biopsy and Polypectomy

Laparoscopy

Hysterosalpingography

Sonohysterography

Male Infertility Diagnosis

Semen Analysis

Endocrine: FSH, Testosterone, and Inhibin B

Anti-Sperm Antibodies (ASA)

Karyotype Chromosome Analysis

Y-Chromosome Microdeletion Test (YCMD)

Pregnancy Tests

Ovulation Kits

Fertility Monitors

Prenatal Diagnostics

Chromopertubation

Amniocentesis

Precursors for Amniocentesis

Chorionic Villus Sampling

Fetal Ultrasound

Transvaginal Fetal Ultrasound

Transabdominal Fetal Ultrasound

6. Technological Developments

Vitrification - A New Method for Long-Term Egg Preservation

Scientists Explore New Technique to Choose Viable Oocytes For Fertilization

Embryonic Stem Cells Produced in Laboratory Have Potential to Treat Infertility

New Media to Assist Oocyte Cryopreservation

Significant Advancements in Embryo Transfer During IVF Procedures

7. Regulatory Environment

Regulations in North America

Food and Drug Administration (FDA)

Centers for Disease Control and Prevention (CDC)

Clinical Laboratories Improvement Amendments (CLIA)

The US State Laws

California

New York

Louisiana

Florida

Professional Agencies

Canada

Regulations in Europe

Germany

The United Kingdom

Italy

Regulations in Asia-Pacific

China

Japan

India

8. Product Innovations/Introductions

Ardana Successfully Completes Phase II Trial for Testosterone Cream

Lilly ICOS Files For EU Approval of Cialis

Serono’s Gonal-F® Obtains Approval in Japan

FDA Approves Organon’s Implanon™ Contraceptive Implant

GroPep Obtains European Patent for PV903

Zonagen Initiates Advanced Clinical Trials for Androxal™

Organon Initiates Phase III Clinical Trials for a New Fertility Hormone

Unipath Launches New Digital Pregnancy Test

Pfizer Receives FDA Nod for Depo-SubQ Provera 104™

Berlex Canada Obtains Approval for Yasmin®

Ardana Offers Striant in Germany

ZNFPC Ally with Indian Company to Launch Oral Contraceptive Products

Global Protection Adds “ONE Condoms©” to its Product Line

Organon Introduces Follistim® AQ in Two New Presentations

Organon Unleashes Follistim® AQ Cartridge for the US Fertility Market

GSK Launches Elogen Pill, Signs Co-Marketing Agreement

Libbs to Launch Oral Contraceptive in Brazil

Repromedix Launches Advanced Tests to Evaluate Male Infertility

Vivus Concludes Phase 2 Clinical Review for Testosterone MDTS

Ardana Bioscience Secures European Approval for Striant

Hubei Pharmaceutical Launches a New Contraceptive

Prasco Launches Cesia, a New Generic Oral Contraceptive

FHC Launches Female Condom in India

DKT Ethiopia Re-Launches Sensation Condoms

FHC Files Patent for Second-Generation Version of the Female Condom

FHC Enters into Agreement with USAID

Barr Laboratories Launches Extended-Cycle Oral Contraceptive, Seasonale

Johnson & Johnson Introduces Evra in UK

Allendale Pharmaceuticals Relaunches Today Sponge

New V-Amour Women's Condom Introduced in Germany

FDA Approves Cialis® for Erectile Dysfunction

Indo-French Lab Unleashes HEyFORTE, A Male Infertility Therapy

Durex Launches Performax Condoms

Ortho-McNeil Introduces Ortho Evra

Pasante Healthcare Launches Pasante Condoms Range

Hindustan Latex Debuts New Lubricated Condoms

Durex Launches 'Easy-on' line of Condoms

Ansell Healthcare Unveils Contempo Lubricated Latex Condoms

Church & Dwight Launches Trojan Her Pleasure Premium Latex Condoms

Organon Debuts NuvaRing contraceptive

Organon Laboratories Introduces Cerazette Pill

Condomania Launches Newly Designed, InSpiral Condoms

Condomania Introduces Pleasure Plus Condoms

Schering Introduces Levonelle in UK

9. Recent Industry Activity

Bayer to Acquire Schering AG

Vitrolife Pockets Medical Device Manufacturer, Swemed

Barr Pharmaceuticals Signs Pact for Al-Sense® Strip

Cigna Approves Essure® System for Reimbursement

Medicaid Offers Coverage for Essure® Procedure

FHC’s Female Condom Clears WHO Hurdle

FHC Bags FC1 Supply Contract from the UNFPA

Female Health Company to Foray the Indian Market

Akzo Nobel to Sell Minority Shares by 2007

Solvay Pharmaceuticals Sells Rowasa®, Balneol®, Anadrol®-50 to Alaven

Zonagen is Now Repros Therapeutics

Acrux Signs Agreement to Market New Contraceptive Spray

Antares Pharma Collaborates with Population Council

IDS Marketing to Launch Okamoto Condom in Thailand

Warner Chilcott Acquired by Investment Group

Ferring Pharmaceuticals, Metris Ink Agreement Over Vorozole

HEG Acquires Minority Stakes in Fertiligent

FHC Offers Second-Generation Female Condoms for YMCA Programs

Conceptus, Gynecare Recoil Co-Promotion Deal

Repromedix Inks Pact with Whitehead Institute to Develop Male Infertility Test

Fertility Centers of Illinois Sets Up New Collaborative Reproduction Center

Ardana Extends HRSU Contract

Mochida to Exclusively Distribute Ortho 777-21 and OrthoM-21 in Japan

Barr Laboratories Obtains Approval for Demulen Tablet

Enhance Biotech Merges with Ardent Pharmaceuticals

Conceptus Kick Starts Co-Promotion Program With Gynecare

Ardana Bioscience Signs Deal for Erectile Dysfunction Drug

Duramed Acquires Exclusive Rights to Nordette®

Berlex Laboratories Renamed Berlex Inc

Duramed Pharmaceuticals Acquire Rights to Loestrin® from Galen

Pfizer Sells Estrostep and Loestrin Contraceptives Business

Ansell Acquires SSL

Serono, AstraZeneca Ally to Develop New Therapy for Female Infertility

Schering AG, Organon Team Up for Male Contraception

Ardana Bioscience Signs Pact with Columbia Laboratories

Carter Wallace Divests Consumer Brands to Armkel

Condomi Enters into a Strategic Joint Venture

Warner-Chilcott Acquires Products from Bristol-Myers

Condomi Acquires French Condom Distributor

Condomi Acquires Condom Brand, Conamore

10. Focus on Select Players

Ardana Limited (UK)

ICOS Corp (US)

Serono S.A. (Switzerland)

Vivus, Inc (US)

Akzo Nobel (The Netherlands)

Organon Inc (US)

Barr Pharmaceuticals, Inc. (US)

Church & Dwight Co., Inc. (US)

Conceptus Inc (US)

Female Health Company (US)

Johnson & Johnson (US)

Ortho-McNeil Pharmaceutical Inc (US)

Okamoto Industries Inc (Japan)

Pfizer Inc. (US)

Schering AG (Germany)

Watson Pharmaceuticals, Inc (US)

Wyeth Corporation (US)

Adeza Biomedical Corporation (US)

Inverness Medical Innovations Ltd (US)

Repromedix Corp (US)

Repros Therapeutics Inc (US)

11. Global Market Perspective

Table 7: World Recent Past, Current & Future Analysis for Fertility Enhancement Drugs by Geographic Region- US, Canada, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 8: World 10-Year Perspective for Fertility Enhancement Drugs by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 9: World Recent Past, Current & Future Analysis for Contraceptives by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Middle East & Africa Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 10: World 10-Year Perspective for Contraceptives by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Middle East & Africa Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 11: World Recent Past, Current & Future Analysis for Contraceptives by Product Segment- Oral Contraceptives, Condoms, and Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 12: World 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, and Implants/Injections Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 13: World Recent Past, Current & Future Analysis for Oral Contraceptives by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Middle East & Africa Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 14: World 10-Year Perspective for Oral Contraceptives by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Middle East & Africa Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 15: World Recent Past, Current & Future Analysis for Condoms by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Middle East & Africa Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 16: World 10-Year Perspective for Condoms by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Middle East & Africa Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 17: World Recent Past, Current & Future Analysis for Implants/Injections by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Middle East & Africa Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 18: World 10-Year Perspective for Implants/Injections by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Middle East & Africa Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 19: World Recent Past, Current & Future Analysis for Reproduction Assisted Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Middle East & Africa Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 20: World 10-Year Perspective for Reproduction Assisted Diagnostics by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Middle East & Africa Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

A. Market Analysis

Outlook

Infertility Market in the US

Competitive Scenario

Table 21: Leading Infertility Pharmaceutical Providers in the US (2004-2005) - Percentage Share Breakdown by Value Sales for Serono Laboratories, Organon Pharmaceuticals, and Others (includes corresponding Graph/Chart)

Table 22: Leading Fertility Diagnostic Providers in the US (2004-2005) - Percentage Share Breakdown by Value Sales for Church & Dwight, Pfizer Consumer Health Division, and Others (includes corresponding Graph/Chart)

Table 23: Leading Players in the US Condoms Market (2004 & 2005) - Percentage Share Breakdown of Sales Revenues for Church & Dwight, SSL, Ansell and Others (includes corresponding Graph/Chart)

Table 24: Pregnancy Test Kits Market in the US: Statistical Findings on Major Players for Year 2005 (includes corresponding Graph/Chart)

ART Facts & Figures

Table 25: Number of Clinics, Cycles Performed, Live-Birth Deliveries, and Infants Born through ART in the US: 2003

Table 26: Number and Outcomes of ART Treatments in the US by Procedure Type: 2003

Table 27: Number of Reported ART Procedures in the US by Patient's State/Territory of Residence During Treatment: 2003

Table 28: Effect of ART on the Number of Infants Born in the US by Plurality: 2003

Table 29: Number and Outcomes of Various ART Procedures in the US (2000): Comparison of In Vitro Fertilization [IVF], Gamete Intrafallopian Transfer [GIFT], Zygote Intrafallopian Transfer [ZIFT], Donor Oocyte, Cryopreserved Embryo Transfer from Donor Oocytes [CPEDO], Cryopreserved Embryo [CPE] Transfer, and ART cycles for Host Uterus Transfer

Table 30: IVF Procedures in the US by Age and Cause of Infertility: 2000

Prevalence of Abortion in the US

Abortion Methods

Abortion Providers

Table 31: Number of Reported Abortions, Abortion Rate and Abortion Ratio in the US: 1995-2000

Contraceptives Market in US

Pill Continues to be One of the Most Popular Forms of Contraception

Condoms - A ‘Fun, Inviting and Pleasurable’ Way to Healthy Life and Lifestyle

Table 32: US Condoms Market (2003): Consumer Purchasing Patterns for Condoms at All Retail Outlets, Drug Stores, Supermarkets, Supercenters, and Discount Stores

Market Trends & Issues

Generics Ransack the Branded Market

Noticeable Shift in Retail Marketing Techniques

Rising Use of Condoms Amongst Teenagers

Changing Attitudes and Perceptions Drive Market Sales

Oral Contraceptives and its Shades of Grey

Marketing Efforts Aimed at Influencing Female College Students

Drug Stores Remain the Choice for Contraceptive Needs

Trade Class Statistics

Table 33: Leading Supermarket Brands in the US Condoms Market (2004 & 2005): Percentage Share Breakdown by Trojan, Trojan-Enz, Lifestyles, Sheik Super, Class-Act, Sheik- Classic, Naturalamb and Others (includes corresponding Graph/Chart)

Table 34: Leading Distribution Channels in the US Condoms Market (2003-2005) - Percentage Share Breakdown by Chain Drug Stores, Discount Stores, Food/Drug Stores, Independent Drug Stores and Supermarkets (includes corresponding Graph/Chart)

Product Introductions

Strategic Corporate Developments

Select US Players

B. Market Analytics

Table 35: US Recent Past, Current & Future Market Analysis for Human Reproductive Technologies by Product Group - Fertility Enhancement Drugs and ART Technologies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 36: US 10-Year Perspective for Human Reproductive Technologies by Product Group- Percentage Breakdown of Dollar Sales for Fertility Enhancement Drugs and ART Technologies for 2000, 2006 & 2010

Table 37: US Recent Past, Current & Future Analysis for Contraceptives by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 38: US 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 39: US Recent Past, Current & Future Analysis for Reproduction Assisted Diagnostics with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

2. Canada

A. Market Analysis

Outlook

Fertility in Canada Dips Too Low for Comfort

Increasing Abortion Rates

Canadian Legislation for ART

Contraceptives Use in Canada

Condoms Market

Product Introductions

Strategic Corporate Development

Select Canadian Players

B. Market Analytics

Table 40: Canadian Recent Past, Current & Future Analysis for Fertility Enhancement Drugs with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 41: Canadian Recent Past, Current & Future Analysis for Contraceptives by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 42: Canadian 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 43: Canadian Recent Past, Current & Future Analysis for Reproduction Assisted Diagnostics with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

3. Japan

A. Market Analysis

Outlook

Explaining the Low Fertility Rates in Japan

ART Procedures in Japan

Japanese Contraceptive Market

Market for Oral Contraceptives Yet to Take Off

Japanese Condom Market

Table 44: Japanese Condoms Shipments (2004 & 2005): Percentage Share Breakdown by Major Players - Okamoto Industries, Sagami Rubber Industries, Fuji Latex Co and Others (includes corresponding Graph/Chart)

Major Issues and Trends

Domestic Products Dominate the Market

Compulsory Labeling of Contraceptives

Late Approval for Use of OCs in Japan

Product Introductions

Select Japanese Players

B. Market Analytics

Table 45: Japanese Recent Past, Current & Future Analysis for Fertility Enhancement Drugs with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 46: Japanese Recent Past, Current & Future Analysis for Contraceptives by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 47: Japanese 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 48: Japanese Recent Past, Current & Future Analysis for Reproduction Assisted Diagnostics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

4. Europe

A. Market Analysis

Outlook

Fertility Patterns in Europe

Infertility Pharmaceutical Market in Europe

ART Procedures in Europe

Europe - A Fertile Market for Infertility Drug Manufacturers

European Condom Market

Market Regulations

Reimbursement Policy in Europe

Product Introductions

Strategic Corporate Developments

B. Market Analytics

Table 49: European Recent Past, Current & Future Analysis for Fertility Enhancement Drugs by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 50: European Recent Past, Current & Future Market Analysis for Human Reproductive Technologies by Product Group - Fertility Enhancement Drugs and ART Technologies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 51: European 10-Year Perspective for Fertility Enhancement Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 52: European 10-Year Perspective for Human Reproductive Technologies by Product Group- Percentage Breakdown of Dollar Sales for Fertility Enhancement Drugs and ART Technologies for 2000, 2006 & 2010

Table 53: European Recent Past, Current & Future Analysis for Contraceptives by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 54: European 10-Year Perspective for Contraceptives by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 55: European Recent Past, Current & Future Market Analysis for Contraceptives by Product Group - Oral Contraceptives, Condoms, and Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 56: European 10-Year Perspective for Contraceptives by Product Group- Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, and Implants/Injections for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 57: European Recent Past, Current & Future Analysis for Reproduction Assisted Diagnostics by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 58: European 10-Year Perspective for Reproduction Assisted Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

4a. France

A. Market Analysis

Outlook

France - The Leading Infertility Pharmaceuticals Market in Europe

IVF Treatment Market In France

Cialis® Tops ED Treatment Market

Condoms Market

B. Market Analytics

Table 59: French Recent Past, Current & Future Analysis for Fertility Enhancement Drugs with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 60: French Recent Past, Current & Future Analysis for Contraceptives by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 61: French 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 62: French Recent Past, Current & Future Analysis for Reproduction Assisted Diagnostics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

4b. Germany

A. Market Analysis

Outlook

Leading Players in German Infertility Drugs Market

German Women Record Highest Usage Rate of Contraceptive Pill

Condoms Market

Product Introductions

Strategic Corporate Developments

Select German Players

B. Market Analytics

Table 63: German Recent Past, Current & Future Analysis for Fertility Enhancement Drugs with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 64: German Recent Past, Current & Future Analysis for Contraceptives by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 65: German 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 66: German Recent Past, Current & Future Analysis for Reproduction Assisted Diagnostics with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

4c. Italy

Market Analysis

Table 67: Italian Recent Past, Current & Future Analysis for Fertility Enhancement Drugs with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 68: Italian Recent Past, Current & Future Analysis for Contraceptives by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 69: Italian 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 70: Italian Recent Past, Current & Future Analysis for Reproduction Assisted Diagnostics with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

4d. The United Kingdom

A. Market Analysis

Outlook

An Update on Contraceptives Market in the UK

Shifting Trends in Contraceptive Use

Role of Pharmacies in Improving Condom Sales

Market Players

Role of Pharmacies in Improving Availability of Condoms and EC Drugs

Regulatory Environment

CEN Standards

Hormonal Contraceptives Restricted by Legislation

Product Introductions

Strategic Corporate Developments

Select UK Players

B. Market Analytics

Table 71: UK Recent Past, Current & Future Analysis for Fertility Enhancement Drugs with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 72: UK Recent Past, Current & Future Analysis for Contraceptives by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 73: UK 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 74: UK Recent Past, Current & Future Analysis for Reproduction Assisted Diagnostics with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

4e. Rest of Europe

A. Market Analysis

Outlook

Contraceptives Market for Select Regions

Russia

Ukraine

Czech Republic

Denmark

Poland

Other European Countries

Strategic Corporate Developments

Select Players in Rest of Europe

B. Market Analytics

Table 75: Rest of Europe Market for Fertility Enhancement Drugs - Recent Past, Current & Future Analysis with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 76: Rest of Europe Market for Contraceptives - Recent Past, Current & Future Analysis by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 77: Rest of Europe 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 78: Rest of Europe Market for Reproduction Assisted Diagnostics - Recent Past, Current & Future Analysis with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

5. Asia-Pacific

A. Market Analysis

Outlook

Asia At a Higher Risk for Teen Pregnancies

Greater Need for Contraception Awareness Among Adolescents

Table 79: Contraceptives Market in Asia-Pacific: Married Adolescent Women Using Reversible* Female Methods (Recent Past Data for 2003)- Percentage Share for Bangladesh, India, Pakistan and Thailand (includes corresponding Graph/Chart)

Table 80: Oral Contraceptives Usage by Married Women (Aged 15-49 years) in East Asia (excluding China), South Central Asia (excluding India), Southeast Asia, India, China, and Asia: Recent Past Data for 2000 (includes corresponding Graph/Chart)

New Sex Determining Pregnancy Test Puts Asia On the Edge

China

Abortion Incidence in China

Contraceptive Market Overview

Increasing Condoms Demand

Role of Foreign Countries in Chinese Condom Market

Ban on Condom Advertising Lifted

India

Regularization of ART in India

High AIDS Prevalence Set to Drive Condom Market

Branded Condom Sales Decline in India

Goli Ke Hamjoli Campaign

Indonesia

Low Levels of Usage

Subsidized Condoms Sap Profits

Australia

New Zealand

Thailand

Thailand to Develop into World’s Leading Condoms Exporter

Worldwide Largest Natural Rubber Cultivation in Thailand

Major Players Rapidly Adapt to Market Dynamics

Thai Health Ministry Playing a Vital Role in Condoms Promotion

Vietnam

Product Introductions

Strategic Corporate Developments

Select Asian Players

B. Market Analytics

Table 81: Asia-Pacific Market for Contraceptives - Recent Past, Current & Future Analysis by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 82: Asia-Pacific 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 83: Asia-Pacific Market for Reproduction Assisted Diagnostics - Recent Past, Current & Future Analysis with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

6. Latin America

A. Market Analysis

Outlook

ART in Latin America

Popular Contraceptives in Latin America and the Caribbean

Table 84: Oral Contraceptives Usage by Married and Sexually Active Unmarried Women (Aged 16-50 years) in Caribbean, Central America, South America, and Latin America: Recent Past Data for 2000

Argentina

Brazil

Contraceptives Market Grows Larger by the Day

Role of Condom Social Marketing (CSM)

Leading Players

Colombia

Ecuador

Mexico

Product Introduction

B. Market Analytics

Table 85: Latin American Market for Contraceptives - Recent Past, Current & Future Analysis by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 86: Latin American 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 87: Latin America Market for Reproduction Assisted Diagnostics - Recent Past, Current & Future Analysis with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

7. Middle East & Africa

A. Market Analysis

Outlook

Penetration of ART in Middle East

Use of Contraceptives

Infertility and ART in Africa

Jamaica

Uganda

Oral Contraceptives Usage Patterns in Near East and Africa

Other Countries

Product Introductions

Strategic Corporate Development

B. Market Analytics

Table 88: Middle East & African Market for Contraceptives - Recent Past, Current & Future Analysis by Product Segment- Oral Contraceptives, Condoms, Implants/Injections Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 89: Middle East & African 10-Year Perspective for Contraceptives by Product Segment - Percentage Breakdown of Dollar Sales for Oral Contraceptives, Condoms, Implants/Injections Markets for 2000, 2006 & 2010 (includes corresponding Graph/Chart)

Table 90: Middle East & African Market for Reproduction Assisted Diagnostics - Recent Past, Current & Future Analysis with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

IV. COMPETITION

1. Acon Laboratories, Inc. (USA)

2. Acrux Ltd. (Australia)

3. Adeza Biomedical Corporation (USA)

Table 91: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 92: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)

Table 93: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 94: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

4. Adiana, Inc. (USA)

5. Advanced Fertility Services (AFS) (USA)

6. Agile Therapeutics, Inc. (USA)

7. Akzo Nobel NV (The Netherlands)

Table 95: First Quarter Sales Analysis: 2005-2006 (In € billion)

Table 96: Annual Sales Analysis: 2004-2005 (In € billion)

Table 97: Annual Sales Analysis by Segment: 2004-2005 (In € billion)

Table 98: Annual Sales Analysis by Geographic Region: 2004-2005 (In € billion)

Organon International, Inc. (USA)

8. Alfa Scientific Designs, Inc. (USA)

9. Ansell Limited (Australia)

Table 99: Annual Sales Analysis: 2004-2005 (In A$ million)

Table 100: Annual Sales Analysis by Business Segment: 2004-2005 (In A$ million)

Table 101: Annual Sales Analysis by Geographic Region: 2004-2005 (In A$ million)

10. Antares Pharma, Inc. (USA)

Table 102: Annual Sales Analysis: 2004-2005 (In US$ million)

11. Apex Medical Technologies, Inc. (USA)

12. Ardana Bioscience (UK)

Table 103: Annual Sales Analysis: 2005-2006 (In £ thousands)

13. AstraZeneca PLC (UK)

Table 104: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 105: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million)

Table 106: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 107: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

14. Barr Pharmaceuticals, Inc. (USA)

Table 108: Annual Sales Analysis: 2004-2006 (In US$ million)

Table 109: Annual Sales Analysis by Quarter: 2005-2006 (In US$ million)

Barr Laboratories, Inc. (USA)

Duramed Pharmaceutical, Inc. (USA)

15. Bayer HealthCare AG (Germany)

Table 110: Annual Sales Analysis: 2004-2005 (In € million)

Table 111: Annual Sales Analysis by Business Segment: 2004-2005 (In € million)

Table 112: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)

16. Beckman Coulter, Inc. (USA)

Table 113: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 114: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 115: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

Table 116: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

17. Biomerica, Inc. (USA)

Table 117: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 118: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)

Table 119: Half Yearly Sales Analysis by Business Segment: 2005-2006 (H1) (In US$ million)

Table 120: Half yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million)

Table 121: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 122: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)

Table 123: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

18. Bioscreen, Inc. (USA)

19. Bristol-Myers Squibb Company (USA)

Table 124: Half yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)

Table 125: Half yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ billion)

Table 126: Half yearly Sales Analysis by Business Segment: 2005-2006 (H1) (In US$ billion)

Table 127: Annual Sales Analysis: 2004-2005 (In US$ billion)

Table 128: Quarterly Sales Analysis: 2004-2005 (In US$ billion)

Table 129: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ billion)

Table 130: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)

20. Casmed International Limited (UK)

21. Cell Robotics International, Inc. (USA)

22. Church & Dwight Co., Inc. (USA)

Table 131: First Quarter Sales Analysis: 2005-2006 (In US$ billion)

Table 132: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion)

Table 133: Annual Sales Analysis: 2004-2005 (In US$ billion)

Table 134: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion)

Table 135: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)

23. Conception Technologies (USA)

24. Conceptus, Inc. (USA)

Table 136: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 137: Annual Sales Analysis: 2004-2005 (In US$ million)

25. Cook Group, Inc. (USA)

26. DKT Ethiopia (Ethiopia)

27. Eli Lilly & Company (USA)

Table 138: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)

Table 139: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ million)

Table 140: Half Yearly Sales Analysis by Product: 2004-2005 (H1) (In US$ million)

Lilly Icos Llc (USA)

28. Embryotech Laboratories, Inc. (USA)

29. Endocare, Inc. (USA)

Table 141: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)

Table 142: Half Yearly Sales Analysis by Product Segment: 2005-2006 (H1) (In US$ million)

Table 143: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 144: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Table 145: Quarterly Sales Analysis: 2004-2005 (In US$ million)

30. Enhance Biotech, Inc. (USA)

31. Female Health Company (USA)

Table 146: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, June) (In US$ million)

Table 147: Nine Months Sales Analysis by Region: 2004-2005 (Nine Months Ended, June) (In US$ million)

32. Ferring Pharmaceuticals AS (Denmark)

Ferring Pharmaceuticals (USA)

33. Fertipro NV (Belgium)

34. Fuji Latex Co., Ltd. (Japan)

35. Galen Limited (UK)

36. Genosis PLC (UK)

37. Genzyme Diagnostics (USA)

38. GlaxoSmithKline PLC (UK)

Table 148: Annual Sales Analysis: 2004-2005 (In £ million)

Table 149: Annual Sales Analysis by Segment: 2004-2005 (In £ million)

Glaxosmithkline Pharmaceuticals Limited (India)

39. Global Protection Corporation (USA)

40. GroPep Limited (Australia)

Table 150: Annual Sales Analysis: 2005-2006 (In US$ million)

Table 151: Annual Sales Analysis by Segment: 2005-2006 (In US$ million)

41. Healthcare Enterprise Group PLC (UK)

Table 152: Annual Sales Analysis: 2004-2006 (In £ million)

Table 153: Annual Sales Analysis by Segment: 2005-2006 (In £ million)

Table 154: Annual Sales Analysis by Segment: 2004-2005 (In £ million)

42. Hubei Pharmaceutical Co., Ltd. (China)

43. ICOS Corporation (USA)

Table 155: First Quarter Sales Analysis: 2005-2006 (In US$ thousand)

Table 156: Annual Sales Analysis: 2004-2005 (In US$ thousand)

Table 157: Annual Sales Analysis by Quarter: 2004-2005 (In US$ thousand)

44. IDS Manufacturing (Thailand) Co., Ltd. (Thailand)

45. Immucon (Canada)

46. IMT International Ltd. (UK)

47. IND Diagnostic, Inc. (Canada)

48. Inntec, Inc. (USA)

49. Inverness Medical Innovations, Inc. (USA)

Table 158: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 159: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 160: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

Table 161: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)

Table 162: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Unipath Ltd. (UK)

50. Johnson & Johnson (USA)

Table 163: Nine Months Sales Analysis: 2004-2005 (Nine Months Ended, September) (In US$ billion)

Table 164: Nine Months Sales Analysis by Segment: 2004-2005 (Nine Months Ended, September) (In US$ billion)

Table 165: Nine Months Sales Analysis by Geographic Region: 2004-2005 (Nine Months Ended, September) (In US$ billion)

Alza Corporation (USA)

Ethicon, Inc. (USA)

Ortho-Mcneil Pharmaceutical, Inc. (USA)

51. Laboratoire Theramex (France)

52. Libbs Farmaceutica (Brazil)

53. Ligand Pharmaceuticals, Inc. (USA)

Table 166: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 167: Annual Sales Analysis: 2003-2005 (In US$ million)

54. Medical Development & Technology BV (The Netherlands)

55. Medi-Cult A/S (Denmark)

56. Metris Therapeutics Ltd. (UK)

57. Mochida Pharmaceutical Co., Ltd. (Japan)

Table 168: Annual Sales Analysis: 2003-2006 (In ¥ million)

58. Novartis AG (Switzerland)

Table 169: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 170: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)

Table 171: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 172: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

Table 173: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

59. Okamoto Industries, Inc. (Japan)

60. Pfizer, Inc. (USA)

Table 174: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)

Table 175: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion)

Table 176: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion)

Table 177: Annual Sales Analysis: 2004-2005 (In US$ billion)

61. Pheromone Sciences Corporation (Canada)

Table 178: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, July) (In Can $ Million)

62. Plextek Ltd. (UK)

63. Polydex Pharmaceuticals Limited (USA)

Table 179: Annual Sales Analysis: 2004-2006 (In US$ million)

Table 180: Quarterly Sales Analysis: 2005-2006 (In US$ million)

64. Prima Biomedical Company (USA)

65. Princeton Biomeditech Corporation (USA)

66. Quidel Corporation (USA)

Table 181: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 182: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 183: Annual Sales Analysis by Product Segment: 2004-2005 (In US$ million)

Table 184: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

67. Reproductive Immunology Associates (USA)

68. Repromedix Corporation (USA)

69. Repros Therapeutics, Inc. (USA)

Table 185: First Quarter Sales Analysis: 2005-2006 (In US$ thousands)

Table 186: Annual Sales Analysis: 2004-2005 (In US$ thousands)

70. Rohto Pharmaceutical Company, Ltd. (Japan)

71. Runbio Biotech Co., Ltd. (China)

72. SA Scientific (USA)

73. Sagami Rubber Industries Co., Ltd. (Japan)

74. Sanofi-Aventis (France)

Table 187: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In € million)

Table 188: Annual Sales Analysis: 2004-2005 (In € million)

Table 189: Annual Sales Analysis by Segment: 2004-2005 (In € million)

Table 190: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)

75. Schering AG (Germany)

Table 191: First Quarter Sales Analysis: 2005-2006 (In € billion)

Table 192: First Quarter Sales Analysis by Segment: 2005-2006 (In € billion)

Table 193: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In € billion)

Table 194: Annual Sales Analysis: 2003-2005 (In € billion)

Table 195: Annual Sales Analysis by Segment: 2004-2005 (In € billion)

Table 196: Annual Sales Analysis by Geographic Region: 2004-2005 (In € billion)

Berlex Laboratories, Inc. (USA)

Berlex Canada, Inc. (Canada)

76. Sefi Medical Instruments (Israel)

77. Select Medical Systems, Inc. (USA)

78. Serono SA (Switzerland)

Table 197: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 198: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

Table 199: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Serono, Inc. (USA)

79. Serum Biotec Ltd. (India)

80. Sigma-Tau Pharmaceuticals, Inc. (USA)

Sigma-Tau Consumer Products (USA)

81. Smiths Medical International Ltd. (UK)

82. Solvay Pharmaceutical, Inc. (USA)

83. Southern Ontario Fertility Technologies (UK)

84. SSL International PLC (UK)

Table 200: Annual Sales Analysis: 2004-2005 (In £ million)

85. Stanbio Laboratory (USA)

86. Syntron Bioresearch, Inc. (USA)

87. Tap Pharmaceutical Products, Inc. (USA)

Table 201: Annual Sales Analysis: 2004-2005 (In US$ million)

88. Theramex (France)

89. Ther-Rx Corporation (USA)

Table 202: Annual Sales Analysis: 2004-2005 (In US$ million)

90. USET Medical Ltd. (Israel)

91. Vitro Diagnostics, Inc. (USA)

92. Vitrolife AB (Sweden)

Swemed (Sweden)

93. Vivus, Inc. (USA)

Table 203: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 204: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 205: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

94. Vysis, Inc. (USA)

95. Warner Chilcott Laboratories (USA)

96. Watson Pharmaceuticals, Inc. (USA)

97. Wyeth (USA)

Table 206: First Quarter Sales Analysis: 2005-2006 (In US$ million)

Table 207: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)

Table 208: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 209: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

98. Zander IVF, Inc. (USA)

99. Zavos Diagnostic Laboratories, Inc. (USA)

100. Zetek (USA)

Abstract

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your personal library immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.